LONDON: US drugmaker Pfizer fought back against criticism that its planned takeover of rival AstraZeneca would damage Britain’s science base by saying strong UK research was a key reason for the deal.
Given its record of big job cuts after past acquisitions, the US group has come under fire in Britain, the United States and Sweden as it weighs its next move to buy AstraZeneca.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!